High-dose erythropoietin population pharmacokinetics in neonates with hypoxic–ischemic encephalopathy receiving hypothermia

2017/01/18 by Adam Frymoyer, Sandra E. Juul, An N. Massaro +3 · 14 citations
Medicine · #Neonatal and fetal brain pathology #Epilepsy research and treatment #Dialysis and Renal Disease Management

paper · pdf · doi:10.1038/pr.2017.15

Citations

• A Comparison of High-Dose Recombinant Erythropoietin Treatment Regimens in Brain-Injured Neonatal Rats

Cited by

• High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol. [europepmc]
• A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses. [europepmc]
• Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens. [europepmc]
• Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia. [europepmc]
• The Effect of Size, Maturation, Global Asphyxia, Cerebral Ischemia, and Therapeutic Hypothermia on the Pharmacokinetics of High-Dose Recombinant Erythropoietin in Fetal Sheep. [europepmc]
• Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review. [europepmc]
• Erythropoietin prevents necrotizing enterocolitis in very preterm infants: a randomized controlled trial. [europepmc]
• Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. [europepmc]
• The Utility of Pharmacometric Models in Clinical Pharmacology Research in Infants. [europepmc]
• Whether Erythropoietin can be a Neuroprotective Agent against Premature Brain Injury: Cellular Mechanisms and Clinical Efficacy. [europepmc]
• New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy. [europepmc]
• A Full Target-Mediated Drug Disposition (TMDD) Model to Explain the Changes in Recombinant Human Erythropoietin (rhEpo) Pharmacokinetics in Patients with Different Bone Marrow Integrity Following Hematopoietic Transplantation. [europepmc]
• The effect of erythropoietin on neonatal hypoxic-ischemic encephalopathy: An updated meta-analysis of randomized control trials. [europepmc]
• Identifying iNOS and glycogen as biomarkers for degenerated cerebellar purkinje cells in autism spectrum disorder: Protective effects of erythropoietin and zinc sulfate. [europepmc]